Considerations on Re-Use of Sterilizing-Grade Filters - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Considerations on Re-Use of Sterilizing-Grade Filters
The author examines re-use of hydrophilic- or hydrophobic-membrane sterilizing-grade filters in liquid sterilizing applications.

Pharmaceutical Technology

Regulatory guidance discourages re-use of sterilization filters, particularly for sterile drug products. Where justified, sterilizing filters may be re-used in some cases, but their re-use must be validated to not compromise filter sterilizing performance or filtrate quality. In addition to basic sterilizing validation studies, as recommended in PDA Technical Report 26 and FDA's aseptic processing guidance, validation of multiply re-used sterilizing filters should include thorough testing of process filters exposed to the maximum specified number of cleaning, resterilization, drying, and re-use cycles. Such testing should include bacterial challenges as well as filter-integrity tests. These tests should assess chemical compatibility of the filter to process fluids and re-use cycle conditions, validity of the integrity test limits under re-use conditions, and include a chemical analysis of rinse effluents to qualify any leaching of bacterial, product, or cleaning agent residues.

Integrity testing alone cannot be relied on to predict sterilizing performance of re-used filters without adequate bacterial challenge validation employing used filter cartridges. Finally, users should consider carefully the level of risk and validation costs involved in satisfactory re-use of sterilizing filters versus the seemingly apparent economics of re-use when designing and qualifying sterilization filtration processes.

Jerold Martin is senior vice-president of Scientific Affairs at Pall Life Sciences, 2200 Northern Blvd., East Hills, NY 11548, tel. 516.801.9086,


1. FDA, Q7A: Guidance for Industry: Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients (Rockville, MD, August 2001).

2. EMEA, Note for Guidance on Good Manufacturing Practice for Active Pharmaceutical Ingredients (London, November 2000).

3. "Current Good Manufacturing Practice for Finished Pharmaceuticals: Equipment Construction" in Code of Federal Regulations, Title 21, Food and Drugs (Government Printing Office, Washington, DC), Part 211, Subpart D, Section 211.65.

4. FDA, Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing: Good Manufacturing Practice (Rockville, MD, Sept. 2004).

5. European Commission, EU Guidelines to Good Manufacturing Practice—Medicinal Products for Human and Veterinary Use, Annex 1, Manufacture of Sterile Medicinal Products (Rev., Brussels, Feb. 2008).

6. PDA, "Sterilizing Filtration of Liquids," Technical Report No. 26 (1998), Revised, 2008, in press.

7. FDA, CDER Warning Letter, Sept. 24, 1999, accessible at, accessed Oct. 20, 2008.

8. FDA, CDER Warning Letter, Aug. 16, 2005, accessible at, accessed Oct. 20, 2008.

9. N. Sweeney, "Sterility Assurance: Optimization of Sterility Assurance Submissions," presented at the Generic Pharmaceutical Association (GPhA) Fall Technical Conference, Bethesda, MD, Oct. 11, 2007.

10. Personal communication.

11. ASTM, "F838-83 Standard Test Method for Determining Bacterial Retention of Membrane Filters Utilized for Liquid Filtration" (Reissued as F838-05), ASTM Book of Standards 11.02 (1983).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here